Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling

Cell Death and Differentiation

Volumn 24, Issue 7, 2017, Pages 1160-1171

  Witt, Axel ^a   Vucic, Domagoj ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES AND PROTEINS; PHOSPHOTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIP KINASE; RIP1 PROTEIN; RIP2 PROTEIN; RIP3 PROTEIN; TOLL LIKE RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE;

CELL DEATH; CELL ORGANELLE; HUMAN; INFLAMMATORY CELL; NECROSOME; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL PROTEIN MODIFICATION; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; ENZYMOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; CELL DEATH; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 85021328801     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.33     Document Type: Review

References (131)

1. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34.
2. Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 2014; 41: 898-908.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
4. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009; 11: 123-132.
5. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep 2008; 9: 536-542.
6. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: A post-Translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011; 12: 439-452.
7. Emmerich CH, Bakshi S, Kelsall IR, Ortiz-Guerrero J, Shpiro N, Cohen P. Lys63/Met1-hybrid ubiquitin chains are commonly formed during the activation of innate immune signalling. Biochem Biophys Res Commun 2016; 474: 452-461.
8. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
9. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009; 78: 363-397.
10. Corn JE, Vucic D. Ubiquitin in inflammation: The right linkage makes all the difference. Nat Struct Mol Biol 2014; 21: 297-300.
11. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
12. Varfolomeev E, Vucic D. Intracellular regulation of TNF activity in health and disease. Cytokine 2016 (e-pub ahead of print).
13. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
14. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243-1252.
15. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010; 29: 4198-4209.
16. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFα)-induced NF-κB activation. J Biol Chem 2008; 283: 24295-24299.
17. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
18. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
19. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 2011; 471: 637-641.
20. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S et al. SHARPIN is a component of the NF-kappaB-Activating linear ubiquitin chain assembly complex. Nature 2011; 471: 633-636.
21. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009; 36: 831-844.
22. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011; 471: 591-596.
23. Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci USA 2016; 113: 10127-10132.
24. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-548.
25. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-473.
26. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires sitespecific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22: 245-257.
27. Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009; 136: 1098-1109.
28. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006; 25: 6685-6705.
29. Wong WW, Gentle IE, Nachbur U, Anderton H, Vaux DL, Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 2010; 17: 482-487.
30. Blackwell K, Zhang L, Workman LM, Ting AT, Iwai K, Habelhah H. Two coordinated mechanisms underlie tumor necrosis factor alpha-induced immediate and delayed IkappaB kinase activation. Mol Cell Biol 2013; 33: 1901-1915.
31. Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem 2006; 281: 13636-13643.
32. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol 2007; 17: 418-424.
33. Komander D, Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J 2008; 409: 77-85.
34. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004; 430: 694-699.
35. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-2354.
36. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2016; 48: 67-73.
37. Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013; 38: 896-905.
38. Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2015; 528: 370-375.
39. Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep 2015; 13: 2258-2272.
40. Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J 2012; 31: 3856-3870.
41. Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH et al. SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling. Mol Cell 2016; 63: 990-1005.
42. Kupka S, De Miguel D, Draber P, Martino L, Surinova S, Rittinger K et al. SPATA2-mediated binding of CYLD to HOIP enables CYLD recruitment to signaling complexes. Cell Rep 2016; 16: 2271-2280.
43. Schlicher L, Wissler M, Preiss F, Brauns-Schubert P, Jakob C, Dumit V et al. SPATA2 promotes CYLD activity and regulates TNF-induced NF-kappaB signaling and cell death. EMBO Rep 2016; 17: 1485-1497.
44. Wagner SA, Satpathy S, Beli P, Choudhary C. SPATA2 links CYLD to the TNF-Alpha receptor signaling complex and modulates the receptor signaling outcomes. EMBO J 2016; 35: 1868-1884.
45. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801.
46. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805.
47. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-796.
48. Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T et al. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 2013; 498: 318-324.
49. Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell 2013; 50: 818-830.
50. Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR et al. The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 2016; 166: 1215-30 e20.
51. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-Alphainduced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
52. Wang L, Du F, Wang X. TNF-Alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
53. Dondelinger Y, Aguileta MA, Goossens V, Dubuisson C, Grootjans S, Dejardin E et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013; 20: 1381-1392.
54. Dondelinger Y, Jouan-Lanhouet S, Divert T, Theatre E, Bertin J, Gough PJ et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol Cell 2015; 60: 63-76.
55. Vlantis K, Wullaert A, Polykratis A, Kondylis V, Dannappel M, Schwarzer R et al. NEMO prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-kappaB-dependent and-independent functions. Immunity 2016; 44: 553-567.
56. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-Alpha. Cell 2009; 137: 1100-1111.
57. Sun X, Yin J, Starovasnik MA, Fairbrother WJ, Dixit VM. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem 2002; 277: 9505-9511.
58. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-1123.
59. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-321.
60. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357-1360.
61. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA 2012; 109: 5322-5327.
62. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
63. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
64. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
65. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007; 131: 669-681.
66. Moulin M, Anderton H, Voss AK, Thomas T, Wong WW, Bankovacki A et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 2012; 31: 1679-1691.
67. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476-5480.
68. Rickard JA, Anderton H, Etemadi N, Nachbur U, Darding M, Peltzer N et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. eLife 2014; 3: e03464.
69. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011; 13: 1437-1442.
70. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13: 705-716.
71. Bonnet MC, Preukschat D, Welz PS, van Loo G, Ermolaeva MA, Bloch Wet al. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35: 572-582.
72. Mahul-Mellier AL, Pazarentzos E, Datler C, Iwasawa R, AbuAli G, Lin B et al. De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. Cell Death Differ 2012; 19: 891-899.
73. Hou X, Wang L, Zhang L, Pan X, Zhao W. Ubiquitin-specific protease 4 promotes TNF-Alpha-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma. FEBS Lett 2013; 587: 311-316.
74. Xu G, Tan X, Wang H, Sun W, Shi Y, Burlingame S et al. Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor alpha-induced nuclear factor kappaB activation via binding to and deubiquitinating receptor-interacting protein 1. J Biol Chem 2010; 285: 969-978.
75. Newton K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol 2015; 25: 347-353.
76. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci USA 2014; 111: 7753-7758.
77. Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PloS ONE 2013; 8: e76841.
78. de Almagro MC, Goncharov T, Izrael-Tomasevic A, Duttler S, Kist M, Varfolomeev E et al. Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death. Cell Death Differ 2017; 24: 26-37.
79. de Almagro MC, Goncharov T, Newton K, Vucic D. Cellular IAP proteins and LUBAC differentially regulate necrosome-Associated RIP1 ubiquitination. Cell Death Dis 2015; 6: e1800.
80. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol 2015; 16: 618-627.
81. Seo J, Lee EW, Sung H, Seong D, Dondelinger Y, Shin J et al. CHIP controls necroptosis through ubiquitylation-And lysosome-dependent degradation of RIPK3. Nat Cell Biol 2016; 18: 291-302.
82. Li D, Xu T, Cao Y, Wang H, Li L, Chen S et al. A cytosolic heat shock protein 90 and cochaperone CDC37 complex is required for RIP3 activation during necroptosis. Proc Natl Acad Sci USA 2015; 112: 5017-5022.
83. Yabal M, Muller N, Adler H, Knies N, Gross CJ, Damgaard RB et al. XIAP restricts TNF-And RIP3-dependent cell death and inflammasome activation. Cell Rep 2014; 7: 1796-1808.
84. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011; 18: 656-665.
85. Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ 2016; 23: 1565-1576.
86. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672.
87. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
88. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5: 503-507.
89. Cusson-Hermance N, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trifdependent toll-like receptor 3 and 4-induced NF-kappa B activation but does not contribute to IRF-3 activation. J Biol Chem 2005; 280: 36560-36566.
90. Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10: 1089-1095.
91. Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268-31279.
92. He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci USA 2011; 108: 20054-20059.
93. Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014; 157: 1189-1202.
94. Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 2015; 6: 6282.
95. Wicki S, Gurzeler U, Wei-Lynn Wong W, Jost PJ, Bachmann D, Kaufmann T. Loss of XIAP facilitates switch to TNFalpha-induced necroptosis in mouse neutrophils. Cell Death Dis 2016; 7: e2422.
96. Masumoto J, Yang K, Varambally S, Hasegawa M, Tomlins SA, Qiu S et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 2006; 203: 203-213.
97. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.
98. Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med 2013; 5: 1278-1295.
99. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF et al. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000; 275: 27823-27831.
100. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J 2008; 27: 373-383.
101. Zinngrebe J, Montinaro A, Peltzer N, Walczak H. Ubiquitin in the immune system. EMBO Rep 2014; 15: 28-45.
102. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 2012; 46: 746-758.
103. Krieg A, Correa RG, Garrison JB, Le Negrate G, Welsh K, Huang Z et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA 2009; 106: 14524-14529.
104. Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol 2015; 39: 115-123.
105. Zeissig Y, Petersen BS, Milutinovic S, Bosse E, Mayr G, Peuker K et al. XIAP variants in male Crohn's disease. Gut 2015; 64: 66-76.
106. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009; 30: 789-801.
107. Yang S, Wang B, Humphries F, Jackson R, Healy ME, Bergin R et al. Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nat Immunol 2013; 14: 927-936.
108. Tao M, Scacheri PC, Marinis JM, Harhaj EW, Matesic LE, Abbott DW. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr Biol 2009; 19: 1255-1263.
109. Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 2007; 282: 36223-36229.
110. Zurek B, Schoultz I, Neerincx A, Napolitano LM, Birkner K, Bennek E et al. TRIM27 negatively regulates NOD2 by ubiquitination and proteasomal degradation. PloS ONE 2012; 7: e41255.
111. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE et al. The ubiquitinediting enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-Triggered signals. Immunity 2008; 28: 381-390.
112. Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M et al. CYLD limits Lys63-And Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling. Cell Rep 2016; 14: 2846-2858.
113. Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 2015; 11: 611-617.
114. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains-from structures to functions. Nat Rev Mol Cell Biol 2009; 10: 659-671.
115. Zhu L, Wang L, Wang X, Zhou L, Liao Z, Xu L et al. Characteristics of A20 gene polymorphisms and clinical significance in patients with rheumatoid arthritis. J Transl Med 2015; 13: 215.
116. Hymowitz SG, Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 2010; 10: 332-341.
117. Codd JD, Salisbury JR, Packham G, Nicholson LJ. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J Pathol 1999; 187: 549-555.
118. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
119. Honma K, Tsuzuki S, Nakagawa M, Karnan S, Aizawa Y, Kim WS et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 2008; 47: 1-7.
120. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-716.
121. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M et al. The NF-{kappa} B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009; 113: 4918-4921.
122. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
123. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981-989.
124. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25: 160-165.
125. Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA et al. A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome. J Invest Dermatol 2003; 121: 732-734.
126. Sundaram K, Shanmugarajan S, Rao DS, Reddy SV. Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone. Endocrinology 2011; 152: 4180-4189.
127. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444: 110-114.
128. Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med 2015; 212: 939-951.
129. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012; 13: 1178-1186.
130. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
131. Stieglitz B, Rana RR, Koliopoulos MG, Morris-Davies AC, Schaeffer V, Christodoulou E et al. Structural basis for ligase-specific conjugation of linear ubiquitin chains by HOIP. Nature 2013; 503: 422-426.